End-Stage Heart Failure
Conditions
Interventions
Case group:None
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with end-stage heart failure who require heart transplantation; (2) No shock and no significant failure of organs other than the heart; (3) Age of enrolled patients between 18 and 75 years.
Exclusion criteria
Exclusion criteria: (1) Patients unable to tolerate surgery or anticoagulant therapy; (2) Patients requiring combined organ transplantation or re-transplantation of the heart; (3)Presence of severe infections or communicable diseases; (4)Patients with uncontrolled psychiatric disorders or cognitive impairments that prevent adherence to treatment; (5) Uncorrected thrombocytopenia or primary coagulopathy (e.g., platelet count 1.6, or PTT >2.5 times the normal control, in the absence of anticoagulant therapy); (6) Presence of severe chronic obstructive pulmonary disease (COPD) (FEV1/FVC 3 mg/dL; ii. Biopsy-confirmed liver cirrhosis or portal hypertension; iii. Serum creatinine exceeds three times the normal limit within 48 hours before enrollment, or the patient requires dialysis (excluding ultrafiltration); (8) History of malignancy; (9) Long-term use of immunosuppressive agents, corticosteroids, antineoplastic drugs, or other medications affecting the immune system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cellular composition of cardiac tissue in end-stage heart failure patients;Transcriptomic profiling of key cardiac cell populations;Alterations in molecular networks and signaling pathways; | — |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction (LVEF);Left ventricular end-diastolic diameter (LVEDD);Left ventricular end-systolic diameter (LVESD);Left atrial diameter (LAD);Interventricular septal thickness (IVST);Left ventricular posterior wall thickness (LVPWT);Left ventricular mass index (LVMI);Left ventricular fractional shortening (LVFS);Left ventricular end-diastolic volume (LVEDV);Left ventricular end-systolic volume (LVESV);Stroke volume (SV);Cardiac output (CO);Cardiac index (CI);Mitral valve E velocity;Mitral valve A velocity;E/A ratio;Early diastolic mitral annular velocity (e');E/e' ratio;Right ventricular systolic pressure (RVSP);Pulmonary artery systolic pressure (PASP);Creatine kinase (CK);Creatine kinase-MB (CK-MB);Lactate dehydrogenase (LDH);Aspartate aminotransferase (AST);Cardiac troponin T (cTnT);Cardiac troponin I (cTnI);Myoglobin (Myo);B-type natriuretic peptide (BNP);N-terminal pro-B-type natriuretic peptide (NT-proBNP);Primary disease type; | — |
Countries
China
Contacts
Public ContactKai Zhang
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed